Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study
NCT07669935
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications [i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)] and risk of adverse outcomes.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- GDM
- Preterm Preeclampsia
- Preeclampsia
- Fetal Growth Restriction (FGR)
- Pregnancy Complications
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 99 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Medicines360
- Last updated on ClinicalTrials.gov
- November 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 2
- Yale New Haven Health System · Bridgeport, CT
- Yale New Haven Health System · New Haven, CT
Louisiana · 1
- Woman's Hospital · Baton Rouge, LA
Texas · 1
- UTHealth Houston · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.